DO
TVTX icon

denkapparat Operations’s Travere Therapeutics TVTX Stock Holding History

denkapparat Operations’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$377K Buy
+6,634
New +$294K 0.12% 301
2026
Q1 		– Sell
-6,634
Closed -$253K – 361
2025
Q4 		$253K Buy
+6,634
New +$216K 0.14% 262

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

denkapparat Operations's TVTX Position: Q2 2026 in Review

denkapparat Operations opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 6,634 shares worth $377K. The stake represents 0.12% of the portfolio and ranks #301 among its holdings. This is a return to the name: denkapparat Operations previously reported a position in TVTX as recently as Q4 2025.

denkapparat Operations first reported a position in TVTX in Q4 2025 and has held it in 2 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • denkapparat Operations held 6,634 shares of Travere Therapeutics worth $377K as of Q2 2026.
  • Travere Therapeutics was a new denkapparat Operations position in Q2 2026.
  • Travere Therapeutics made up 0.12% of denkapparat Operations's portfolio in Q2 2026, its #301 holding.
  • denkapparat Operations first reported a position in Travere Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on denkapparat Operations's 13F filing for Q2 2026, filed 6 Aug 2026.